Portfoliotracker

Citius Oncology, Inc.

CTOR · NASDAQCM · Healthcare Drug Manufacturers - Specialty & Generic 0/100 E

0,535 $
▼ −0,039 (−6,76 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:24
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap57,7 mil. $ P/E– Forward P/E– P/S8,1 P/B1,4 EV/EBITDA– Dividend yield– FCF yield-55,68 % EPS-0,48 $ Net margin0,0 % Return on equity-126,6 % Beta3,58 Debt / equity0,25
52-week range 0,49 to 1,83
3-month average volume0,1 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Country
United States
Fiscal year end
30. 9.
Data since
8. 12. 2022

Explore further

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account